Total Liabilities Summary of Azitra, Inc.

Azitra, Inc.'s latest annual total liabilities in 2023 was 2.2 Million USD , down -94.93% from previous year.
Azitra, Inc.'s latest quarterly total liabilities in 2024 Q2 was 2.15 Million USD , up 23.66% from previous quarter.
Azitra, Inc. reported annual total liabilities of 43.42 Million USD in 2022, up 20.74% from previous year.
Azitra, Inc. reported annual total liabilities of 35.96 Million USD in 2021, down 0.0% from previous year.
Azitra, Inc. reported quarterly total liabilities of 1.74 Million USD for 2024 Q1, down -20.82% from previous quarter.
Azitra, Inc. reported quarterly total liabilities of 2.15 Million USD for 2023 Q3, down -16.78% from previous quarter.

Annual Total Liabilities Chart of Azitra, Inc. (2023 - 2021)

Name	Total Liabilities	Total Liabilities Difference
AIM ImmunoTech Inc.	9.14 Million USD	75.923%
Ampio Pharmaceuticals, Inc.	2.37 Million USD	7.309%
Armata Pharmaceuticals, Inc.	142.02 Million USD	98.449%
Actinium Pharmaceuticals, Inc.	45.06 Million USD	95.113%
Can-Fite BioPharma Ltd.	3.74 Million USD	41.208%
Chromocell Therapeutics Corporation	6.54 Million USD	66.33%
Calidi Biotherapeutics, Inc.	18.25 Million USD	87.935%
CEL-SCI Corporation	17.31 Million USD	87.28%
iBio, Inc.	7.41 Million USD	70.279%
Lineage Cell Therapeutics, Inc.	38.99 Million USD	94.352%
MAIA Biotechnology, Inc.	7.08 Million USD	68.934%
Matinas BioPharma Holdings, Inc.	46.33 Million USD	95.247%
Navidea Biopharmaceuticals, Inc.	12.51 Million USD	82.402%
NovaBay Pharmaceuticals, Inc.	5.72 Million USD	61.498%
NanoViricides, Inc.	1.35 Million USD	-62.083%
Oragenics, Inc.	1.79 Million USD	-22.476%
BiomX Inc.	55.07 Million USD	96.001%
BiomX Inc.	55.07 Million USD	96.001%
Protalix BioTherapeutics, Inc.	50.86 Million USD	95.67%
Palatin Technologies, Inc.	10.85 Million USD	79.709%
Scorpius Holdings, Inc.	22.74 Million USD	90.317%
Theriva Biologics, Inc.	20.51 Million USD	89.264%